论文部分内容阅读
Nowadays,advanced non-small cell lung cancer (NSCLC) is still an incurable disease.However,recent researches on maintenance therapy have led to considerable progress.Recently,pemetrexed and erlotinib have been approved for maintenance chemotherapy by both the U.S.Food and Drug Administration and European Medicines Agency.However,there are not adequate data to support the maintenance therapy as the standard treatment for advanced NSCLC and there has been no conclusive predictor of who will get benefit from maintenance chemotherapy and what type of maintenance,continuation or switch,is preferred.This article reviews the main studies on maintenance therapy of advanced NSCLC and discusses the results available to date.
Nowadays, advanced non-small cell lung cancer (NSCLC) is still an incurable disease. Despite, recent researches on maintenance therapy have led to considerable progress. Remingly, pemetrexed and erlotinib have been approved for maintenance chemotherapy by both the US Food and Drug Administration and European Medicines Agency. Despite, there are not adequate data to support the maintenance therapy as the standard treatment for advanced NSCLC and there has been no conclusive predictor of who will get benefit from maintenance chemotherapy and what type of maintenance, continuation or switch, is preferred.This article reviews the main studies on maintenance therapy of advanced NSCLC and discusses the results available to date.